Hints and tips:
...Shaw Research (DESRES) today announced that it has entered into an exclusive global license agreement with Eli Lilly and Company (Lilly) for the clinical development and commercialization of DESRES’s program...
...Eric Schmidt at Cowen, writes: “We would expect a deal will ultimately be consummated at a modest premium to the initial offer [perhaps $75-$80 (a) share].”...
International Edition